ECOG-ACRIN EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

Objective

ECOG-ACRIN EA8231: A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer.

National Clinical Trial (NCT) Number: 06524544

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT06524544

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Genitourinary Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]